MorphoSys AG — Earnings Release 2011

Oct 28, 2011

Q3 2011 – Conference Call

October 28, 2011

Today on the Call

Simon Moroney CEO

Jens Holstein CFO

Arndt Schottelius CDO

Claudia Gutjahr-Löser

Head of Corporate Communications & IR

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

Q3 2011: Pipeline Update

MOR202 – dosing of first multiple myeloma patient in phase 1/2a trial

MOR103 – phase 1 study in MS and study for subcutaneous formulation in preparation

MOR208 – preliminary data in 2012

Second clinical milestone with Bayer HealthCare in another cancer ADC program

BAY79-4620 stopped, Bayer HealthCare keeps the target license

Novartis advances antibody into phase 2

Amyloid imaging data for Gantenerumab

78 Therapeutic Antibody Programs Ongoing, 19 in Clinical Trials

Q3 2011: AbD Serotec Update

AbD Serotec and Merck expand existing license agreement

AbD Serotec signs research and supply agreement with Dana-Farber Cancer Institute

Agreement with the Moredun Institute and the Roslin Research Institute in the UK

Consolidated Income Statement (IFRS)

in million € (differences due to rounding)	9 Months 2011	9 Months 2010	Δ
Revenues	83.7	62.8	+33%
Cost of Goods Sold	5.5	5.5
R&D Expenses*	41.9	32.5	+29%
S,G&A Expenses	16.8	16.8
Total Operating Expenses	64.1	54.8	+17%
Other Operating Income	0.3	0.02
Profit from Operations	19.9	8.0	+149%
Non-operating (Expenses)/Income	(0.9)	2.2
Profit before Taxes	19.0	10.2	+86%
Income Tax Expense	6.0	3.0
Net Profit	13.0	7.2	+81%
Diluted net Profit per Share	0.56	0.32

* including investment in proprietary product and technology development 9 Months 2011: € 26.1 million (9 Months 2010: € 19.4 million)

in million € (differences due to rounding)	9 Months 2011	9 Months 2010
Partnered Discovery
Segment Revenues	67.9	47.4
Operating Expenses	17.1	16.0
Segment Result	50.9	31.4
Proprietary Development
Segment Revenues	1.9	1.1
Operating Expenses	25.0	18.4
Other Operating Income	0.3	0
Segment Result	(22.9)	(17.3)
AbD Serotec
Segment Revenues	14.1	15.0
Operating Expenses	13.8	14.4
Segment Result	0.4	0.7

in million € (differences due to rounding)	Sep 30, 2011	Dec 31, 2010
Assets
Cash, Cash Equivalents & Marketable Securities	143.0	108.4
Accounts Receivables	11.6	15.0
Other Current Assets	8.3	9.1
Total Non-current Assets	76.7	80.0
Total Assets	239.7	212.6
Liabilities
Total Current Liabilities	29.4	21.4
Total Non-current Liabilities	10.1	5.3
Total Shareholders' Equity	200.2	185.9
Total Liabilities	239.7	212.6

Group revenue guidance: slightly below € 105 million Group operating profit: € 10–13 million Updated Confirmed MOR202: Publish MOR202 pre-clinical data at ASCO Start of phase 1 study in multiple myeloma MOR103: Complete enrollment of Phase 1b/2a in RA Start Phase 1b in multiple sclerosis patients Start PK study for subcutaneous administration 1-3 partner INDs Data from ongoing trials of partnered programs First diagnostic kit based on a HuCAL antibody will be launched 2nd IND in Q3

Further technology announcements

New deal(s) based on Slonomics technology

© MorphoSys AG MorphoSys

Outlook for 2011

Questions & Answers

Thank You

www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, arYla®, RapMAT® and AutoCAL® are registered trademarks of MorphoSys AG